The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study).
 
Tejal Amar Patel
No Relationships to Disclose
 
Joe Ensor
Consulting or Advisory Role - Aetna; StatAnalytics IDD
 
Sarah Creamer
No Relationships to Disclose
 
Angel Augusto Rodriguez
No Relationships to Disclose
 
Polly Ann Niravath
Honoraria - Genomic Health
Consulting or Advisory Role - Novartis
 
Jorge German Darcourt
No Relationships to Disclose
 
Virginia G. Kaklamani
Honoraria - Celgene; Eisai; Genentech; Genomic Health; Novartis; Pfizer
Speakers' Bureau - Celgene; Eisai; Genentech
Research Funding - Eisai
 
Jane Lowe Meisel
No Relationships to Disclose
 
Xiaoxian Li
No Relationships to Disclose
 
John G. Kuhn
Consulting or Advisory Role - TG Therapeutics
Research Funding - Methodist Health System Dallas Texas
 
Roberto R Rosato
No Relationships to Disclose
 
Anna Belcheva
No Relationships to Disclose
 
Toniva Boone
No Relationships to Disclose
 
Jenny Chee Ning Chang
No Relationships to Disclose